396 related articles for article (PubMed ID: 24809951)
1. [Iron deficiency anemia and anemia of chronic disease (ACD)].
Hiller E
Dtsch Med Wochenschr; 2014 May; 139(22):1163-70; quiz 1171-4. PubMed ID: 24809951
[No Abstract] [Full Text] [Related]
2. [Iron deficiency anaemia].
Füessl HS
MMW Fortschr Med; 2014 Feb; 156(3):55-7. PubMed ID: 24938067
[No Abstract] [Full Text] [Related]
3. [What is essential in diagnosis?].
MMW Fortschr Med; 2014 Jun; 156(12):54-5. PubMed ID: 25369688
[No Abstract] [Full Text] [Related]
4. [Not Available].
Plate A
Praxis (Bern 1994); 2016 Nov; 105(24):1443-1444. PubMed ID: 27911655
[No Abstract] [Full Text] [Related]
5. [Efficacy and tolerability of ferric carboxymaltose in geriatric patients with anemia. Data from three non-interventional studies].
Röhrig G; Steinmetz T; Stein J; Geisel T; Virgin G; Schaefer R; Bach M; Schulz RJ
MMW Fortschr Med; 2014 Jul; 156 Suppl 2():48-53. PubMed ID: 25351027
[TBL] [Abstract][Full Text] [Related]
6. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
[TBL] [Abstract][Full Text] [Related]
7. Iron deficiency and its management in patients undergoing lipoprotein apheresis. Comparison of two parenteral iron formulations.
Schatz U; Arneth B; Siegert G; Siegels D; Fischer S; Julius U; Bornstein SR
Atheroscler Suppl; 2013 Jan; 14(1):115-22. PubMed ID: 23357152
[TBL] [Abstract][Full Text] [Related]
8. [Iron deficiency in chronic heart failure: from diagnosis to therapy].
von Haehling S; Anker SD
Dtsch Med Wochenschr; 2014 Apr; 139(16):841-4. PubMed ID: 24722935
[TBL] [Abstract][Full Text] [Related]
9. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial.
Kulnigg S; Stoinov S; Simanenkov V; Dudar LV; Karnafel W; Garcia LC; Sambuelli AM; D'Haens G; Gasche C
Am J Gastroenterol; 2008 May; 103(5):1182-92. PubMed ID: 18371137
[TBL] [Abstract][Full Text] [Related]
10. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL
J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875
[TBL] [Abstract][Full Text] [Related]
11. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia.
Bregman DB; Morris D; Koch TA; He A; Goodnough LT
Am J Hematol; 2013 Feb; 88(2):97-101. PubMed ID: 23335357
[TBL] [Abstract][Full Text] [Related]
12. Clinical perspective: iron replacement therapy in chronic heart failure.
Cowie MR; Lucas R
Int J Clin Pract; 2011 Jun; 65(6):645-8. PubMed ID: 21564435
[No Abstract] [Full Text] [Related]
13. Efficacy, safety and prognostic benefit of intravenous iron therapy with ferric carboxymaltose in patients with heart failure and left ventricular dysfunction.
Robles-Mezcua A; González-Cruces N; Ruiz-Salas A; Morcillo-Hidalgo L; Robledo-Carmona J; Gómez-Doblas JJ; de Teresa E; García-Pinilla JM
Int J Cardiol; 2016 Jan; 202():118-20. PubMed ID: 26397399
[No Abstract] [Full Text] [Related]
14. Ferric carboxymaltose approved for iron deficiency anemia.
Thompson CA
Am J Health Syst Pharm; 2013 Sep; 70(17):1458. PubMed ID: 23943169
[No Abstract] [Full Text] [Related]
15. Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: a prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index.
Skikne BS; Punnonen K; Caldron PH; Bennett MT; Rehu M; Gasior GH; Chamberlin JS; Sullivan LA; Bray KR; Southwick PC
Am J Hematol; 2011 Nov; 86(11):923-7. PubMed ID: 21812017
[TBL] [Abstract][Full Text] [Related]
16. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease.
Beigel F; Löhr B; Laubender RP; Tillack C; Schnitzler F; Breiteneicher S; Weidinger M; Göke B; Seiderer J; Ochsenkühn T; Brand S
Digestion; 2012; 85(1):47-54. PubMed ID: 22179489
[TBL] [Abstract][Full Text] [Related]
17. Soluble transferrin receptor and sTfR-F index for assessing concurrent iron deficiency in patients with chronic renal failure.
Choi JW
Ann Hematol; 2008 Jul; 87(7):575-6. PubMed ID: 18317758
[No Abstract] [Full Text] [Related]
18. [Indications and practical management of parenteral iron therapy].
Kosch M; Schaefer RM
Wien Klin Wochenschr; 2003 Jun; 115(11):380-4. PubMed ID: 12879735
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia.
Breymann C; Gliga F; Bejenariu C; Strizhova N
Int J Gynaecol Obstet; 2008 Apr; 101(1):67-73. PubMed ID: 18234203
[TBL] [Abstract][Full Text] [Related]
20. Iron and vitamin D deficiency in inflammatory bowel disease.
Ghaly S
J Gastroenterol Hepatol; 2016 Jun; 31 Suppl 1():27-8. PubMed ID: 27273035
[No Abstract] [Full Text] [Related]
[Next] [New Search]
